Latest news with #RoW
New Indian Express
19-07-2025
- Business
- New Indian Express
Delhi govt appoints PWD nodal officer to fast-track 5G, broadband infra rollout
NEW DELHI: In a major push to strengthen broadband infrastructure and accelerate 5G deployment in the city, Delhi government has appointed a nodal officer within the Public Works Department (PWD) to coordinate with the State Broadband Committee. The committee, functioning under the Ministry of Communication, addresses challenges faced by telecom service providers in setting up towers and laying optical fibre cables in urban areas. This move comes after a meeting held last year where central authorities asked departments like the PWD to designate officials responsible for handling connectivity-related clearances. 'The newly appointed nodal officer will focus on clearing pending permissions related to Right of Way (RoW)' a key requirement for laying underground optical fibre and erecting telecom towers,' officials said. To streamline infrastructure, the committee has directed the Urban Development Department to ensure that all agencies planning excavation work inform the relevant authorities beforehand.
Time of India
18-07-2025
- Business
- Time of India
PWD appoints nodal officer to fast-track strengthening broadband services in Delhi
New Delhi: In a major push to strengthen broadband infrastructure and accelerate 5G deployment in the city, the Delhi government has appointed a nodal officer within the Public Works Department (PWD) to coordinate with the State Broadband Committee . The committee, functioning under the Ministry of Communication, addresses challenges faced by telecom service providers in setting up towers and laying optical fiber cables in urban areas. This move comes after a meeting held last year where central authorities asked departments like the PWD to designate officials responsible for handling connectivity-related clearances. "The newly appointed nodal officer will focus on clearing pending permissions related to Right of Way (RoW) - a key requirement for laying underground optical fiber and erecting telecom towers," officials said. To further streamline infrastructure development, the committee has directed the Urban Development Department to ensure that all agencies planning excavation work inform the relevant authorities beforehand. This measure aims to minimize disruption and inconvenience to the public, officials said further. The Delhi government has also directed telecom operators to expedite the rollout of 5G services, particularly in central parts of the city, including the New Delhi area. This directive aligns with the national goal of achieving comprehensive 5G coverage across major urban centers. The efforts are likely improve digital connectivity in the capital and help meet the growing demand for high-speed internet and advanced mobile services.
Time of India
11-07-2025
- Business
- Time of India
Pharmexcil flags export disruption risk due to COPP mandate; seeks urgent review
The Pharmaceuticals Export Promotion Council of India on Friday sought a review of a recent circular issued by the Central Drugs Standard Control Organisation, which mandates exclusive online submission of Certificate of Pharmaceutical Product (COPP) applications via the ONDLS portal . While the Council supports digital integration and modernisation of regulatory frameworks, it foresees a major disruption to India's pharmaceutical exports , particularly to Rest of World (RoW) markets, if the mandate is abruptly enforced without a transitional roadmap for exporters. Currently, Indian exports to RoW markets account for 45 per cent of total exports. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Is it legal? How to get Internet without paying a subscription? Techno Mag Learn More Undo "Exporters are now burdened with a dual regulatory bottleneck - domestically through CDSCO 's NOC/new drug classification delays, and internationally due to slower regulatory submissions and approvals abroad," Pharmexcil DG K Raja Bhanu said in a statement. The council has formally requested the Ministry of Health & Family Welfare and CDSCO to delay the implementation of the ONDLS-only COPP submission model and engage in immediate stakeholder consultations, he added. Live Events "This request has been made keeping in mind that regulatory policies must strike a balance between maintaining stringent quality standards and being trade-facilitative," Bhanu said. While the government rightly aspires to ensure responsible manufacturing, some of the regulatory developments are misperceived by industry players as commercial limitations, he said. The inability to secure timely COPP approvals or No Objection Certificates (NOCs) has the potential to push overseas buyers toward alternate suppliers from competing nations, causing irreversible long-term damage to Indian exporters, he added.
Time of India
27-06-2025
- Business
- Time of India
Two 6-lane flyovers to run parallel to Nagpur Metro viaducts on NH-44
Nagpur: Changing the urban transport infrastructure of the city, MahaMetro and the National Highways Authority of India (NHAI) signed a Memorandum of Understanding ( MoU ) to enable the construction of Metro viaducts and parallel two 6-lane flyovers along critical stretches of the national highway as part of the Nagpur Metro Rail Project Phase 2 on Friday. The MoU, signed at the NHAI regional office in Nagpur, allows MahaMetro to use NHAI's Right of Way (RoW) for constructing elevated Metro corridors along two key routes — from Jamtha to Butibori on NH-44 (Butibori stretch) and from HB Town to Transport Nagar on NH-53 (Pardi stretch). On the Butibori stretch, the Metro viaducts and the two proposed 6-lane flyovers will be integrated in terms of structural planning but will not follow a double-decker design. A senior MahaMetro official clarified that, unlike the double-decker arrangements seen on Wardha Road or the Kamptee corridor, the Metro and flyovers here will run parallel to each other. In specific sections, such as underpasses, they will share substructures to make optimal use of space and reduce overall costs. However, the design plans and cost estimates are still being finalised and remain subject to change, the official added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Thị trường có dấu hiệu suy thoái không? IC Markets Đăng ký Undo Two flyovers, each around 2 km long, are planned along this route — one in front of the VCA Stadium at Jamtha and the other near Dongargaon. Additionally, the Metro line will cross over an existing railway track near Borkhedi. At this location, due to the presence of a previously constructed railway overbridge, the Metro crossing will create a structure that may appear similar to a double-decker, a senior NHAI official said. The stretch between Jamtha and Butibori, measuring around 10 km, includes approximately 8 km where the Metro viaduct will run directly along NH-44. However, before Metro construction can fully commence on this stretch, realignment of the highway's centre portion is required. MahaMetro is currently carrying out that work as part of the road widening initiative. A senior MahaMetro official told TOI, "The widening is being done to facilitate Metro work. We have already started the road widening and once that is completed and we have two additional lanes available for traffic, we will begin erecting the Metro pillars. The flyover and Metro construction will then proceed simultaneously without disrupting highway traffic." NHAI, on its part, has extended full support for the execution of the project. A senior NHAI official confirmed, "We have made officially extended cooperation to MahaMetro and will be providing backend support whenever needed. All required permissions from our side have already been granted, and we've facilitated utility shifting and other procedures." The MoU also sets clear provisions for adherence to Indian Road Congress (IRC) guidelines, including a minimum 6-metre vertical clearance for vehicles and the use of independent engineers and joint inspections to ensure quality, safety, and coordination between agencies. The agreement was signed at the NHAI office by Rakesh Prakash Singh (CGM & RO, NHAI), Naresh Gurbani (executive director, MahaMetro), and R Arun Kumar (executive director, MahaMetro). Officials emphasised that the initiative reflects a shared vision to integrate mass transit solutions with national highway development — helping reduce congestion and cater to the needs of Nagpur's rapidly expanding population.
&w=3840&q=100)
Business Standard
12-06-2025
- Business
- Business Standard
Eris soars 11% on Thursday, zooms 61% from low; is it time to book profit?
Share price of Eris Lifesciences today Shares of Eris Lifesciences hit a new high of ₹1,909.55, surging 11 per cent on the BSE in Thursday's intra-day trade in an otherwise weak market. The stock of this pharmaceutical company was trading higher for the third straight day, soaring 17 per cent during the period. It has bounced back 61 per cent from its April month low of ₹1,187.10 on the BSE. At 02:13 PM; Eris was quoting 3 per cent higher at ₹1,777, as compared to 1.1 per cent decline in the BSE Sensex. The average trading volumes at the counter jumped multiple-fold with a combined 2.92 million shares changing hands on the NSE and BSE. Is it time to book profit in Eris Lifesciences? Currently, Eris trades above PL Capital's target price of ₹1,740 per share. Post March 2025 quarter (Q4FY25) earnings, the brokerage firm on May 20, 2025 had recommended a 'Buy' rating on Eris. The company has multiple growth levers such as broad-based offerings in the derma segment, tapping Glucagon-like peptide 1 (GLP-1) market, demand supply mismatch in insulin segment, creating large injectable franchise across India and Rest of the World (RoW) market and benefits of operating leverage, as revenue scales up from these acquisitions, the brokerage firm said. Eris guided for a 15 per cent organic year-on-year (YoY) growth to reach ₹2,900-₹3,000 crore in revenue in FY26. The EBITDA margin in this business is expected to be 37 per cent (+50bp YoY as per cent of sales). Eris indicated Swiss Parenterals business to the tune of ₹380 crore-₹390 crore (growth of 15-20 per cent YoY) with an EBITDA margin of 35 per cent for FY26. It targeted a net debt of ₹1,800 crore at the end of FY26 vs. ₹2,200 crore at the end of FY25. During FY24-25, Eris progressed to secure building blocks in the Diabetes/ Obesity treatment through achieving regulatory milestones, building in-house capacity for manufacturing, and enhancing its marketing reach. Further, it is building capacity and is in the process of getting relevant regulatory approvals for international business in the injectable segment. Considering these factors and the reduction in financial leverage, Motilal Oswal Financial Services estimate a 15 per cent/17 per cent/44 per cent CAGR in sales/EBITDA/PAT over FY25-27. The brokerage firm in the Q4 results update said that they reiterate 'Neutral' rating on Eris with a target price of ₹1,350 per share. Meanwhile, India Ratings and Research (Ind-Ra) expects the scale of operations to remain healthy and EBITDA margins to be steady in the medium term, with benefits emanating from the backward integration initiatives. Also, Ind-Ra remains positive on the recent acquisitions/initiatives in the biologics/glucagon-like peptide space albeit with contribution likely to be playing out FY27/FY28 onwards. Ind-Ra believes the chronic therapy portfolio typically has seen higher stickiness among patients, leading to higher profitability in the long term. Ind-Ra expects the net leverage to have reduced below 2.5x during FY25 and will reduce further to 2.0x in FY26, in the absence of acquisition-led debt. The improvement in credit metrics will be supported by robust operating profitability led by integration benefits in lieu of recent acquisitions. ' About Eris Lifesciences Eris, a 100 per cent domestic formulation (DF) company, was established in 2007. The company focuses on the branded generics business in the chronic (87 per cent of sales) and acute segments (13 per cent of sales). The company has drugs across therapies such as anti-diabetes, cardiovascular, dermatology, gastroenterology and gynaecology, anti-infectives, vitamins, and other therapeutic areas.
